Verastem flags RAMP 201 biomarker data for late-breaking oral presentation at IGCS 2026
VSTM•Verastem said new molecular profiling and tumor biomarker analysis from Phase 2 RAMP 201 in recurrent low-grade serous ovarian cancer will be presented Oct. 2, 2026, at the IGCS Annual Global Meeting.
1. Presentation scheduled
The findings will be presented in a late-breaking oral session at the IGCS Annual Global Meeting on Oct. 2, 2026. An oral presentation of previously reported Phase 2 RAMP 201J results in Japanese patients is also scheduled at the meeting.
